Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature

Durieux, Valérie; Coureau, Michelle; Meert, Anne-Pascale; Berghmans, Thierry; Sculier, Jean-Paul

doi:10.1016/j.lungcan.2017.01.015

Cited by 15 publications

(12 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date prediction of response to immune checkpoint inhibitors is difficult and available predictive markers are not optimal. Secondly cancer may be associated with a number of autoimmune manifestations either as a paraneoplastic condition (1) or as comorbidities. In experimental models, knocking-out CTLA-4 results in a massive proliferation and lymphocytic infiltration of tissues (2) while PD-1 knock-down mice are prone to autoimmune disease [reviewed in (3)].…”

Section: Introductionmentioning

confidence: 99%

“…The most frequent manifestations found were rheumatoid arthritis (5.9%), psoriasis (2.8%), polymyalgia rheumatica (1.8%), Addison disease (1%), systemic lupus erythematosus (SLE-−0.9%), ulcerative colitis (0.8%), giant cell arteritis (0.8%), sicca syndrome (0.6%), regional enteritis (0.5%), and Meniere disease (0.5%). However, these autoimmune manifestations can be very broad as it has been recently reviewed for lung cancer in a series of articles curated by Jean Paul Scuiler (1,(8)(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

et al. 2020

Self Cite

View full text Add to dashboard Cite

Immunotherapy is an important armamentarium for cancer treatment nowadays. Apart from their significant effectiveness in controlling disease they also generate potential severe immune related adverse effects. Preexistence of immune related conditions may eventually predispose to the development of more severe complication and extreme caution have been taken in treating these patients. We performed a literature review searching for case reports and case series in order to offer evidence-based data for clinical management of these patients. Preexisting serological-only immune abnormalities or presence of a predisposing genetic background does not seem to confer significant risk but existing data is scarce. Most patients with preexistent autoimmune diseases can probably treated with checkpoint inhibitors as they seem to have at least the same response rate as the general cancer population. Under treatment, a significant part of them (at least 30%) can experience a flare of their baseline disease which can sometime be severe. Life-threatening cases seems rare and disease flare can be generally managed with steroids. The volume of available data is more important for rheumatologic diseases than for inflammatory bowel diseases were more caution should be observed. However, it has to be kept in mind that new immune related adverse effects (IrAE) are seen with a similar frequency as the flare of the baseline disease. Both flare-up's and newly developed IrAE are generally manageable with a careful clinical follow-up and prompt therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies suggest that up to 8% of patients with cancer may have a paraneoplastic syndrome (9). Symptoms of a paraneoplastic syndrome can affect any organ system, including haematological (e.g., haemolytic anaemia), cutaneous (e.g., scleroderma, clubbing), vascular (e.g., leucocytoclastic vasculitis, Raynaud's phenomenon) and neurological systems (e.g., neuropathies or encephalomyelitis, stiff-man syndrome) (10). Common rheumatological manifestations include hypertrophic osteoarthropathy, cancer associated myositis, paraneoplastic polyarthritis, and relapsing seronegative symmetric synovitis with pitting oedema (RS3PE) (6).…”

mentioning

confidence: 99%

The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome

et al. 2018

View full text Add to dashboard Cite

The aim of this study was to systematically consider the evidence for polymyalgia rheumatica (PMR) as a paraneoplastic disease. A systematic review of Medline and Embase was conducted from their inception to February 2017. Risk of bias was assessed using the Newcastle-Ottawa tool. Data were extracted regarding the PMR-cancer association, the types of cancer associated with PMR and the presentation of PMR patients subsequently diagnosed with cancer. Twenty-three full text articles were reviewed from the 1174 unique references identified in the search. Nine articles were included in the final review. There was some evidence of an association between PMR and cancer in the short-term (first 6 to 12 months after diagnosis), but no evidence of an association after this time. Limited evidence suggests that lymphoma, prostate and haematological cancers may be those cancers more commonly diagnosed in those with PMR. There was little evidence to suggest what presenting features may be associated with the development of cancer. There is little evidence of PMR as a true paraneoplastic disease. However, there is reason to be cautious when making the diagnosis of PMR. Clinicians should be aware of this potential association both prior to making a diagnosis and throughout the course of the condition.

show abstract

“…In our patient's case, the hypothesis of a paraneoplastic origin is proposed. Many autoimmune paraneoplastic syndromes are well described in the literature (7) and some paraneoplastic dermatoses are ANTICANCER RESEARCH 39: xxx-xxx (2019) well-known. However, with the arrival of ICIs in oncology, the distinction between autoimmune paraneoplastic syndrome and irAEs induced by immunotherapy has become challenging.…”

Section: Discussionmentioning

confidence: 99%

Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature

Cited by 15 publications

References 46 publications

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome

Bullous Lupus Under Nivolumab Treatment for Lung Cancer: A Case Report With Systematic Literature Review

Contact Info

Product

Resources

About